As tranylcypromine is an SSAO and LSD inhibitor, there is therefore an opportunity to check the potential anti-obesity properties of this drug and its novel derivatives in studies performed to test anti-cancer or anti-inflammatory properties. This evidence concerns the gene DNASE1L3 and obesity disorder.